Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Top Method for starting the Morning - 2UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 3'You're no longer my sister' - rows erupt as war divides Iranian families
- 4The Best Games Crossroads in History
- 5Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- In the background: Visiting Notable Film Areas All over the Planet
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Auschwitz Committee wants German auction of Holocaust items scrapped
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
- SF Chinatown's historic Empress of China building being revived into cultural campus
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- 2024 Manual for Light Extravagance Room Feel: What's Moving
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
